| Ytd | -15.41% | |
| 1y | -13.20% |
| Open | 15.89 | Prev Close | 15.77 | Low | 15.82 | High | 16.00 | Mkt Cap | 2.98B |
| Vol | 1.12M | Avg Vol | 1.68M | EPS | 1.79 | P/E | 8.89 | Forward P/E | 7.99 |
| Beta | 0.74 | Short Ratio | 7.19 | Inst. Own | 33.89% | Dividend | 1.88 | Div Yield | 11.92 |
| Ex Div Date | 05-14 | Earning | 07-30 | 50-d Avg | 15.64 | 200-d Avg | 16.81 | 1yr Est | 19.36 |
EMERYVILLE, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT
In the closing of the recent trading day, Hercules Capital (HTGC) stood at $15.58, denoting a +2.23%
-- $135 million equity financing with participation from leading specialist investors, corporate inv
The $300m facility backed by top-tier lenders reflects strong conviction in Perk's vision to bui